Home Cart Sign in  
Chemical Structure| 927822-86-4 Chemical Structure| 927822-86-4

Structure of KC7F2
CAS No.: 927822-86-4

Chemical Structure| 927822-86-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

KC7F2 is a selective HIF-1α transcription inhibitor with IC50 of 20 μM in a cell-based assay.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of KC7F2

CAS No. :927822-86-4
Formula : C16H16Cl4N2O4S4
M.W : 570.38
SMILES Code : O=S(C1=CC(Cl)=CC=C1Cl)(NCCSSCCNS(C2=CC(Cl)=CC=C2Cl)(=O)=O)=O
MDL No. :MFCD22683809
InChI Key :REQLACDIZMLXIC-UHFFFAOYSA-N
Pubchem ID :16047442

Safety of KC7F2

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of KC7F2

epigenetics

Isoform Comparison

Biological Activity

Target
  • HIF

    HIF-1α, IC50:20 μM

  • HIF1

    HIF-1α, IC50:20 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
Neural Stem Cells (NSCs) 20 μmol/L 24 hours KC7F2 significantly inhibited DDAH1-upregulated ChAT activity, suggesting that the HIF-1α/Chat signaling pathway may be involved in DDAH1-promoted neurogenesis. PMC11119513
NCoR1 depleted tolerogenic DCs 10μM 6 hours Inhibition of HIF-1α-driven glycolysis, reducing the secretion of tolerogenic cytokines PMC9804250
LN229 various concentrations (above 20 μM) 6 hours KC7F2 significantly inhibited HIF-1α protein levels, especially at concentrations above 20 μM. PMC2770235
U251MG, MCF7, PC3, LNZ308 40 μM 8 or 24 hours KC7F2 significantly inhibited HIF-1α protein levels. PMC2770235
ARPE-19 cells 10 µM 72 hours KC7F2 significantly improved the maximal respiration and spare respiratory capacity in ARPE-19 cells treated with adv-HTRA1, and reduced glycolysis and glycolytic capacity. PMC10265780
VSMCs 40 μM 1 hour KC7F2 significantly suppressed HIF-1α protein expression and subsequent VEGF, μMP-2, and μMP-9 protein expression PMC6909961
Mesenchymal stem cells 20 μM 24 hours To investigate the role of KC7F2 on HIF-1α and CXCR4/7 signaling in hypoxia-preconditioned MSCs, results showed that KC7F2 inhibited hypoxia-preconditioning-induced upregulation of CXCR4 and CXCR7 and increased levels of apoptosis-associated proteins caspase-3 and cleaved-caspase-3. PMC9288720
human umbilical vein endothelial cells (HUVEC) 10 μM 12 hours KC7F2 inhibited VEGF-induced HUVEC cell proliferation and did not affect that in the control group. PMC9202333

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice NCoR1 deficient mouse model Intraperitoneal injection 100 mg/kg/day and 200 mg/kg/day Once daily for 28 days Combined inhibition of HIF-1α and CPT1a significantly reduced bacterial burden in lung DCs and increased Th1 response in the spleen PMC9804250
Mice hHTRA1-Tg mice Intraperitoneal injection 300 mg/kg three times a week for 18 days KC7F2 improved the retinal function and alleviated RPE damage in hHTRA1-Tg mice treated with NaIO3. PMC10265780
C57BL/6J mice oxygen-induced retinopathy (OIR) model intraperitoneal injection 40 mg/kg Elacridar, 80 mg/kg Sunitinib once daily for 2-3 weeks KC7F2 significantly attenuated pathological neovascularization in OIR mice and decreased the number of preretinal neovascular cell nuclei without changing the avascular area. PMC9202333

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.75mL

0.35mL

0.18mL

8.77mL

1.75mL

0.88mL

17.53mL

3.51mL

1.75mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories